scispace - formally typeset
C

Chirag G. Patil

Researcher at Cedars-Sinai Medical Center

Publications -  123
Citations -  6058

Chirag G. Patil is an academic researcher from Cedars-Sinai Medical Center. The author has contributed to research in topics: Mortality rate & Hazard ratio. The author has an hindex of 42, co-authored 118 publications receiving 5248 citations. Previous affiliations of Chirag G. Patil include Stanford University & VA Palo Alto Healthcare System.

Papers
More filters
Journal ArticleDOI

Epidemiology and the Global Burden of Stroke

TL;DR: The global burden of stroke is high, inclusive of increasing incidence, mortality, DALYs, and economic impact, particularly in low- and middle-income countries.
Journal ArticleDOI

Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma

TL;DR: This paper evaluated the safety and immune responses to an autologous dendritic cell vaccine pulsed with class I peptides from tumorassociated antigens (TAA) expressed on gliomas and overexpressed in their cancer stem cell population.
Journal ArticleDOI

Late recurrences of Cushing's disease after initial successful transsphenoidal surgery.

TL;DR: A quarter of the patients with Cushing's disease who achieve surgical remission after transsphenoidal surgery, recur with long-term follow-up, emphasizing the need for continued biochemical and clinical follow- up to ensure remission after surgery.
Journal ArticleDOI

Risk factors for postoperative spinal wound infections after spinal decompression and fusion surgeries.

TL;DR: This multivariate analysis of a large prospectively collected database of patients who underwent a spinal decompression and fusion between 1997 and 2006 demonstrated the high mortality, morbidity, and hospitalization costs associated with postoperative spinal wound infections.
Journal ArticleDOI

Whole brain radiation therapy (WBRT) alone versus WBRT and radiosurgery for the treatment of brain metastases.

TL;DR: This review restricted the review to randomized controlled trials (RCTs) that compared use of W BRT plus SRS versus WBRT alone for upfront treatment of adults with newly diagnosed metastases (single or multiple) in the brain resulting from any primary, extracranial cancer.